About Amicus Therapeutics, Inc. - Common Stock (FOLD)
Amicus Therapeutics is a biotechnology company focused on developing innovative therapies for rare and orphan diseases, particularly genetic disorders. Their primary emphasis lies in the advancement of treatments for conditions such as Pompe disease and Fabry disease. The company utilizes proprietary technologies to create enzyme replacement therapies and small molecule pharmacological chaperones, aiming to address unmet medical needs and improve the lives of patients with these challenging conditions. Through a commitment to research and development, Amicus Therapeutics seeks to make significant strides in the field of precision medicine. Read More
BioMedWire Editorial Coverage : Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with the National Institutes of Health estimating that more than 30 million people nationwide are living with a rare disease. Most of these conditions have no FDA-approved therapies, leaving older adults particularly at risk as age-related changes can mask or delay accurate diagnosis. This growing strain on care has heightened the need for novel treatments that address significant unmet medical needs. Soligenix Inc. (NASDAQ: SNGX) ( profile ), a late-stage biopharmaceutical developer, is advancing several rare-disease therapies, including HyBryte[TM] (synthetic hypericin) for cutaneous T-cell lymphoma (“CTCL”), where it is currently running the final confirmatory trial necessary before seeking global marketing authorization. As the Trump administration pursues new health-policy measures focused on chronic and rare diseases, Soligenix’s programs are positioned at a pivotal crossroads of scientific innovation and national healthcare goals. The company is working alongside several prominent leaders in the pharmaceutical and life sciences sectors, including AMGEN Inc. (NASDAQ: AMGN), Amicus Therapeutics Inc. (NASDAQ: FOLD), Citius Oncology Inc. (NASDAQ: CTOR) and…
AUSTIN, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with the National Institutes of Health estimating that more than 30 million people nationwide are living with a rare disease. Most of these conditions have no FDA-approved therapies, leaving older adults particularly at risk as age-related changes can mask or delay accurate diagnosis. This growing strain on care has heightened the need for novel treatments that address significant unmet medical needs. Soligenix Inc. (NASDAQ: SNGX) (Profile), a late-stage biopharmaceutical developer, is advancing several rare-disease therapies, including HyBryte[TM] (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL), where it is currently running the final confirmatory trial necessary before seeking global marketing authorization. As the Trump administration pursues new health-policy measures focused on chronic and rare diseases, Soligenix’s programs are positioned at a pivotal crossroads of scientific innovation and national healthcare goals. The company is working alongside several prominent leaders in the pharmaceutical and life sciences sectors, including AMGEN Inc. (NASDAQ: AMGN), Amicus Therapeutics Inc. (NASDAQ: FOLD), Citius Oncology Inc. (NASDAQ: CTOR) and Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP).
Amicus Therapeutics (FOLD) beats Q3 2025 earnings estimates with strong revenue growth and a major milestone in profitability, driving positive market momentum.
PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.
PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to discuss financial results for the quarter ended September 30, 2025.
PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September.
NetworkNewsWire Editorial Coverage : As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population’s increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose. Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for years. There are more than 30 million Americans who have a rare disease, so there is a growing need for accurate diagnoses and effective treatments. The Trump administration’s “Make America Healthy Again” initiatives have highlighted this problem and focused on improving access to treatments and speeding up medical innovation. Soligenix Inc. (NASDAQ: SNGX) ( Profile ) is working to advance this mission with its HyBryte(“TM”) platform, a new therapy for cutaneous T-cell lymphoma (“CTCL”), a rare form of skin cancer that largely impacts older adults. The company has successfully established U.S.-based manufacturing for HyBryte’s active ingredient, demonstrating the kind of domestic innovation that can significantly help this underserved patient group. Soligenix is one of several notable companies dedicated to making an impact in the pharmaceutical field, alongside Amgen Inc. (NASDAQ: AMGN), Amicus Therapeutics Inc. (NASDAQ: FOLD), Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and…
Amicus Therapeutics (FOLD) beats Q2 2025 revenue and EPS estimates, driven by strong growth in Galafold and Pompe disease therapies, sparking a 2.77% pre-market rally.
PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2025.
PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) in Muscle and Nerve. In this new publication, based on a within group effect-size analysis, subjects who switched from alglucosidase alfa to cipa+mig achieved improvements or stability in most of the outcomes measured.
PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June.
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2025 Health Care Conference in Las Vegas, NV on Wednesday, May 14, 2025, at 8:00 a.m. P.T.
